← stocks-llm New chat

ETON PHARMACEUTCIALS INC (ETON) — insider trading

Health Care · NASDAQ

ETON PHARMACEUTCIALS INC (ETON) has 42 reported SEC Form 4 insider transactions in our data, including 17 open-market sales among the most recent 42 (latest 2026-07-14).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-07-14 Opaleye Management Inc. 10% owner Open-market sale 13,315 $37.54 $499.9K Form 4/A
2026-07-14 Opaleye Management Inc. 10% owner Open-market sale 15,000 $37.54 $563.1K Form 4/A
2026-07-14 Opaleye Management Inc. 10% owner Open-market sale 13,315 $37.54 $499.9K Form 4
2026-07-14 Opaleye Management Inc. 10% owner Open-market sale 15,000 $37.54 $563.1K Form 4
2026-07-14 BRYNJELSEN SEAN Director, Officer (President & CEO) Option exercise / conversion (derivative) 200,000 $0.00 $0 Form 4
2026-07-14 BRYNJELSEN SEAN Director, Officer (President & CEO) Option exercise / conversion 200,000 $1.37 $274.0K Form 4
2026-07-12 BRYNJELSEN SEAN Director, Officer (President & CEO) Option exercise / conversion (derivative) 27,500 $0.00 $0 Form 4
2026-07-12 BRYNJELSEN SEAN Director, Officer (President & CEO) Option exercise / conversion 27,500 Form 4
2026-07-12 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 10,000 $0.00 $0 Form 4
2026-07-12 Krempa David Officer (Chief Business Officer) Option exercise / conversion 10,000 Form 4
2026-07-07 Opaleye Management Inc. 10% owner Open-market sale 6,685 $38.37 $256.5K Form 4
2026-07-07 Opaleye Management Inc. 10% owner Open-market sale 20,000 $38.37 $767.5K Form 4
2026-07-06 Opaleye Management Inc. 10% owner Open-market sale 10,000 $38.00 $380.0K Form 4
2026-07-02 Opaleye Management Inc. 10% owner Open-market sale 25,000 $37.39 $934.6K Form 4
2026-07-02 Opaleye Management Inc. 10% owner Open-market sale 65,000 $37.39 $2.43M Form 4
2026-06-26 Krempa David Officer (Chief Business Officer) Grant / award / vesting (derivative) 10,000 $0.00 $0 Form 4
2026-06-17 Adams Jennifer McKie Director Option exercise / conversion (derivative) 50,000 $0.00 $0 Form 4
2026-06-17 Adams Jennifer McKie Director Open-market sale 50,000 $32.48 $1.62M Form 4
2026-06-17 Adams Jennifer McKie Director Option exercise / conversion 50,000 $3.78 $189.0K Form 4
2026-05-28 BRYNJELSEN SEAN Director, Officer (President & CEO) Open-market sale 148 $32.67 $4.8K Form 4
2026-05-28 BRYNJELSEN SEAN Director, Officer (President & CEO) Open-market sale 119,852 $31.88 $3.82M Form 4
2026-05-27 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 7,203 $0.00 $0 Form 4
2026-05-27 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 12,476 $0.00 $0 Form 4
2026-05-27 Krempa David Officer (Chief Business Officer) Open-market sale 19,679 $31.47 $619.4K Form 4
2026-05-27 Krempa David Officer (Chief Business Officer) Option exercise / conversion 7,203 $3.58 $25.8K Form 4
2026-05-27 Krempa David Officer (Chief Business Officer) Option exercise / conversion 12,476 $1.37 $17.1K Form 4
2026-05-26 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 12,524 $0.00 $0 Form 4
2026-05-26 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 25,000 $0.00 $0 Form 4
2026-05-26 Krempa David Officer (Chief Business Officer) Open-market sale 37,524 $31.49 $1.18M Form 4
2026-05-26 Krempa David Officer (Chief Business Officer) Option exercise / conversion 12,524 $1.37 $17.2K Form 4
2026-05-26 Krempa David Officer (Chief Business Officer) Option exercise / conversion 25,000 $1.38 $34.5K Form 4
2026-05-22 Krempa David Officer (Chief Business Officer) Option exercise / conversion (derivative) 30,591 $0.00 $0 Form 4
2026-05-22 Krempa David Officer (Chief Business Officer) Open-market sale 519 $35.00 $18.2K Form 4
2026-05-22 Krempa David Officer (Chief Business Officer) Open-market sale 9,315 $33.88 $315.6K Form 4
2026-05-22 Krempa David Officer (Chief Business Officer) Open-market sale 32,963 $33.22 $1.10M Form 4
2026-05-22 Krempa David Officer (Chief Business Officer) Option exercise / conversion 30,591 $3.58 $109.5K Form 4
2026-04-21 RIEDEL NORBERT G Director Option exercise / conversion (derivative) 19,655 $0.00 $0 Form 4
2026-04-21 RIEDEL NORBERT G Director Option exercise / conversion (derivative) 12,500 $0.00 $0 Form 4
2026-04-21 RIEDEL NORBERT G Director Option exercise / conversion 19,655 $8.61 $169.2K Form 4
2026-04-21 RIEDEL NORBERT G Director Option exercise / conversion 12,500 $7.31 $91.4K Form 4
2026-02-03 RIEDEL NORBERT G Director Option exercise (in/at-the-money) (derivative) 30,000 $0.00 $0 Form 4
2026-02-03 RIEDEL NORBERT G Director Option exercise (in/at-the-money) 30,000 $4.42 $132.6K Form 4

Ask the chat about ETON's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: ETON PHARMACEUTCIALS INC (ETON).

Last updated 2026-07-14 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.